9
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Assessment of Lipophilicity Descriptors of Selected NSAIDs Obtained at Different TLC Stationary Phases

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Lipophilicity study of selected NSAIDs, the group of the bioactive compounds usually used in humans and animals medicine, with the use of experimental and calculation methods was evaluated. LogP values are proposed and compared as descriptors of the lipophilicity of eleven compounds (from oxicams and coxibs). Obtained data were designated by thin-layer chromatography (TLC) in various chromatographic conditions, with stationary phases with different properties. The mobile phase systems were prepared by mixing the respective amounts of water and organic modifier, methanol and acetone, in the range of 30 to 80% ( v/ v) in 5% increments. Retention parameters (R F, R M and R M0) were calculated and statistically evaluated to establish correlations. All experimentally determined R M0 values were compared with partition coefficients obtained by computational methods using linear regression analysis. Moreover, in order to extract information about the lipophilicity of compounds from large retention datasets, two chemometric approaches, namely principal component analysis (PCA) and cluster analysis (CA) were carried out. Established models of lipophilicity may have the potential to predict the biological activity of a number of drugs. The presented knowledge may also be of use during drug discovery processes, broadening the knowledge of potential ways to modify the physicochemical properties of chemical compounds.

          Related collections

          Most cited references72

          • Record: found
          • Abstract: found
          • Article: not found

          The influence of lipophilicity in drug discovery and design.

          The role of lipophilicity in drug discovery and design is a critical one. Lipophilicity is a key physicochemical property that plays a crucial role in determining ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties and the overall suitability of drug candidates. There is increasing evidence to suggest that control of physicochemical properties such as lipophilicity, within a defined optimal range, can improve compound quality and the likelihood of therapeutic success. This review focuses on understanding lipophilicity, techniques used to measure lipophilicity, and summarizes the importance of lipophilicity in drug discovery and development, including a discussion of its impact on individual ADMET parameters as well as its overall influence on the drug discovery and design process, specifically within the past 15 years. A current review of the literature reveals a continued reliance on the synthesis of novel structures with increased potency, rather than a focus on maintaining optimal physicochemical properties associated with ADMET throughout drug optimization. Particular attention to the optimum region of lipophilicity, as well as monitoring of lipophilic efficiency indices, may contribute significantly to the overall quality of candidate drugs at different stages of discovery.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships

            Non-steroidal anti-inflammatory drugs (NSAIDs) are the competitive inhibitors of cyclooxygenase (COX), the enzyme which mediates the bioconversion of arachidonic acid to inflammatory prostaglandins (PGs). Their use is associated with the side effects such as gastrointestinal and renal toxicity. The therapeutic anti-inflammatory action of NSAIDs is produced by the inhibition of COX-2, while the undesired side effects arise from inhibition of COX-1 activity. Thus, it was though that more selective COX-2 inhibitors would have reduced side effects. Based upon a number of selective COX-2 inhibitors (rofecoxib, celecoxib, valdecoxibetc.) were developed as safer NSAIDs with improved gastric safety profile. However, the recent market removal of some COXIBs such as rofecoxib due to its adverse cardiovascular side effects clearly encourages the researchers to explore and evaluate alternative templates with COX-2 inhibitory activity. Recognition of new avenues for selective COX-2 inhibitors in cancer chemotherapy and neurological diseases such as Parkinson and Alzheimer’s diseases still continues to attract investigations on the development of COX-2 inhibitors. This review highlights the various structural classes of selective COX-2 inhibitors with special emphasis on their structure-activity relationships.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Use of NSAIDs in treating patients with arthritis

              Patients with rheumatic diseases, including rheumatoid arthritis and osteoarthritis, almost universally describe pain and stiffness as important contributors to reduced health-related quality of life. Of the treatment options available, NSAIDs are the most widely used agents for symptomatic treatment. NSAIDs are effective anti-inflammatory and analgesic drugs by virtue of their ability to inhibit biosynthesis of prostaglandins at the level of the cyclooxygenase enzyme. However, many of the adverse effects of NSAIDs are also related to inhibition of prostaglandin production, making their use problematic in some patient populations. For the clinician, understanding the biology of prostaglandin as it relates to gastrointestinal, renal, and cardiovascular physiology and the pharmacologic properties of specific NSAIDs is key to using these drugs safely. Of particular importance is the recognition of co-morbid conditions and concomitant drugs that may increase the risk of NSAIDs in particular patients. In patients with risk factors for NSAID toxicity, using the lowest dose of a drug with a short half-life only when it is needed is likely to be the safest treatment option. For those patients whose symptoms cannot be managed with intermittent treatment, using protective strategies is essential.
                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Journal
                Pharmaceutics
                Pharmaceutics
                pharmaceutics
                Pharmaceutics
                MDPI
                1999-4923
                24 March 2021
                April 2021
                : 13
                : 4
                : 440
                Affiliations
                [1 ]Department of Inorganic and Analytical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland; tryptofan56@ 123456gmail.com (M.Z.); monika.1.dabrowska@ 123456uj.edu.pl (M.D.)
                [2 ]Department of Pharmaceutical Chemistry, Medical University of Gdańsk, Hallera 107, 80-416 Gdańsk, Poland; aplenis@ 123456gumed.edu.pl
                Author notes
                [* ]Correspondence: m.starek@ 123456uj.edu.pl
                Author information
                https://orcid.org/0000-0003-0637-0611
                https://orcid.org/0000-0002-0507-2770
                Article
                pharmaceutics-13-00440
                10.3390/pharmaceutics13040440
                8064060
                33805056
                ee27f0a5-64be-43d0-8671-e7c0116b4fe6
                © 2021 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 25 February 2021
                : 21 March 2021
                Categories
                Article

                lipophilicity,nsaids,thin-layer chromatography,chemometric methods,stationary phases

                Comments

                Comment on this article